ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.192,19
-0,10%
S&P 500
5.650,59
0,34%
US Dollar vs BRL
5,4136
-0,64%
Bitcoin
63.870,44
-1,51%
Brent Oil
83,11
-1,46%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH
DataHoraFonteTítuloCódigoCompanhia
05/05/201017:10Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/201017:05Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/201017:00Business WireAllos Therapeutics Reports First Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/05/201016:22Edgar (US Regulatory)Confidential Treatment Order (CT ORDER)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/04/201007:06Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/04/201018:40Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/04/201009:00Business WireAllos Therapeutics Appoints Dr. Charles Morris as Chief Medical OfficerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/04/201009:00Business WireAllos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
14/04/201018:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/04/201017:34Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/03/201018:20Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/03/201018:46Edgar (US Regulatory)Annual Report (10-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/03/201018:00Business WireAllos Therapeutics Reports Fourth Quarter and Full Year 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/02/201011:01Business WireAllos Therapeutics to Participate in RBC Capital Markets Health Care ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/02/201011:00Business WireAllos Therapeutics to Report Fourth Quarter and Full Year 2009 Results on March 1, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/02/201020:35Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/02/201015:48Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/02/201016:25PR Newswire (US)MedNet Solutions Deploys Global Peripheral T-cell Lymphoma Registry for Allos TherapeuticsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/02/201011:00Business WireAllos Therapeutics to Present at BIO CEO & Investor ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/01/201011:00Business WireAllos Therapeutics to Present at J.P. Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200909:25MarketwiredWall St Sense Offers In-depth Research on the Services, Financial and Healthcare Sectors' Key PlayersNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/12/200912:15Business WireAllos Therapeutics’ FOLOTYN™ Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Ly...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200916:22Dow Jones News2nd UPDATE: Celgene To Buy Gloucester Pharma for At Least $340 MillionNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/12/200913:00Business WireAllos Therapeutics’ FOLOTYN™ Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Tre...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/12/200913:00Business WireAllos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN™ at 51st ASH Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/200911:00Business WireAllos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN™ (pralatrexate injection)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/12/200911:00Business WireAllos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematolo...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/11/200911:00Business WireAllos Therapeutics Announces Issuance of U.S. Patent for FOLOTYNNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/11/200909:38MarketwiredRidgewater Equity Reviews the Following Equities Human Genome Sciences Inc., Intuit Inc., Advanced Battery Technologies, Linn EnNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/11/200911:00Business WireAllos Therapeutics Announces New Data on FOLOTYN™ to be Presented at the American Society of Hematology MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

Seu Histórico Recente

LSE
0SE5
Sensirion
NASDAQ
BCEL
Atreca
LSE
ESO
Epe Special Opportunities
LSE
HAN
Hansa Investment
LSE
AT1
Ivz At1 Capbond
LSE
EEJD
Is Jpn Ee Ud
LSE
TR3G
Iv Ust 1-3 D Gb
NASDAQ
SATC
NASDAQ
NFLD
Northfield labs
NYSE
AZZ
AZZ
NYSE
HASI
HA Sustainable Infrastru...
NYSE
MI
Marshall & Ilsley
BOV
WLMM3
WLM ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados